Julia Andresen

Julia Andresen

Auto-generated profile, based on publicly available information

Julia Andresen

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, 40225 Duesseldorf, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AKAnnika Kasprzak
Annika Kasprzak
JAJulia Andresen
Julia Andresen
KNKathrin Nachtkamp
Kathrin Nachtkamp
AKAndrea Kündgen
Andrea Kündgen
FSFelicitas Schulz
Felicitas Schulz
UGUlrich Germing
Ulrich Germing
Despite notable advancements in infection prevention and treatment, individuals with hematologic malignancies still face the persistent threat of frequent and life-threatening complications. Those undergoing chemotherapy or other disease-modifying therapies are particularly vulnerable to developing infectious complications, increasing the risk of mortality. Myelodysplastic syndromes (MDS) predominantly affect the elderly, with the incidence rising with age and peaking at around 70 years. Patients with MDS commonly present with unexplained low blood-cell counts, primarily anemia, and often experience varying degrees of neutropenia as the disease progresses. In our subsequent retrospective study involving 1593 patients from the Düsseldorf MDS Registry, we aimed at outlining the incidence of infections in MDS patients and identifying factors contributing to heightened susceptibility to infectious complications in this population.